Literature DB >> 1493350

Should older patients with acute myocardial infarction receive thrombolytic therapy?

B D Williamson1, D W Muller, E J Topol.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1493350     DOI： 10.2165/00002512-199202060-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  25 in total

1.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

Review 2.  Selection of patients with acute myocardial infarction for thrombolytic therapy.

Authors:  D W Muller; E J Topol
Journal:  Ann Intern Med       Date:  1990-12-15       Impact factor: 25.391

3.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

4.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

5.  Stroke after acute myocardial infarction: relation to infarct size.

Authors:  P L Thompson; J S Robinson
Journal:  Br Med J       Date:  1978-08-12

6.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.

Authors:  J M Gore; M Sloan; T R Price; A M Randall; E Bovill; D Collen; S Forman; G L Knatterud; G Sopko; M L Terrin
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

7.  In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

8.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

9.  Myocardial infarction and stroke.

Authors:  M S Komrad; C E Coffey; K S Coffey; R McKinnis; E W Massey; R M Califf
Journal:  Neurology       Date:  1984-11       Impact factor: 9.910

10.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Authors:  A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094
View more
  3 in total

Review 1.  Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.

Authors:  K Ramanathan; C J Ellis; H D White
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 2.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 3.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.